文献速递肝病

Emricasan治疗NASH相关肝硬化伴严重门脉高压的随机安慰剂对照试验

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
PubMed 文献 · J Hepatol · 2019-12-21

本研究为多中心双盲随机安慰剂对照试验,纳入263例NASH相关肝硬化且基线HVPG≥12 mmHg的患者,随机接受emricasan 5 mg、25 mg、50 mg每日两次或安慰剂治疗48周。主要终点为第24周HVPG变化,结果显示各剂量组与安慰剂组无显著差异,但代偿期患者及基线HVPG较高者可能获益,药物安全耐受。

要点

  • Emricasan未能显著改善NASH肝硬化伴严重门脉高压患者的HVPG。
  • 代偿期患者及基线HVPG较高者可能呈现小幅治疗效应。
  • Emricasan安全性良好,不良事件与安慰剂组相似。

核心结论

  • Emricasan虽降低生物标志物提示靶点结合,但未改善HVPG或临床结局。
  • 代偿期且基线HVPG较高的患者有证据显示小幅治疗效应。
  • Emricasan治疗安全且耐受性良好。

研究设计与样本

  • 多中心双盲随机安慰剂对照试验,纳入263例NASH相关肝硬化且基线HVPG≥12 mmHg的患者。
  • 按1:1:1:1随机接受emricasan 5 mg、25 mg、50 mg每日两次或安慰剂,治疗最长48周。
  • 主要终点为第24周HVPG变化(ΔHVPG)。

主要发现

  • 各剂量组与安慰剂组ΔHVPG无显著差异(分别为-0.21、-0.45、-0.58 mmHg),校正基线HVPG、代偿状态和非选择性β受体阻滞剂使用。
  • 代偿期患者(n=201[76%])HVPG下降趋势更明显(emricasan所有剂量 vs 安慰剂,p=0.06)。
  • 基线HVPG较高者HVPG下降更显著(p=0.018),基线HVPG与治疗存在显著交互作用(连续变量p=0.024;二分类以16 mmHg为界p=0.013)。
  • 生物标志物在第24周显著下降,但第48周恢复至基线水平。
  • 新发或恶化失代偿事件(中位暴露337天期间约10%)、MELD和Child-Pugh评分进展及治疗中出现的不良事件在各组间相似。

关键数值与推荐

  • 严重门脉高压定义为HVPG≥12 mmHg。
  • 主要终点为第24周ΔHVPG,各剂量组与安慰剂组无显著差异。
  • 代偿期患者HVPG下降的组间比较p=0.06。
  • 基线HVPG与治疗交互作用:连续变量p=0.024,二分类(16 mmHg)p=0.013。

临床怎么用

  • 不推荐使用emricasan改善NASH相关肝硬化伴严重门脉高压患者的HVPG或临床结局。
  • 对于代偿期且基线HVPG较高的患者,emricasan可能具有小幅治疗效应,但需进一步验证。

局限性

  • 生物标志物下降仅在第24周短暂出现,第48周恢复至基线。
  • 代偿期患者和基线HVPG较高者的治疗效应仅为探索性发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in an open-label study in patients with cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG) ≥12 mmHg. We aimed to confirm these results in a placebo-controlled study in patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis. METHODS: We performed a multicenter double-blinded study, randomizing 263 patients with NASH-related cirrhosis and baseline HVPG ≥12 mmHg to twice daily oral emricasan 5 mg, 25 mg, 50 mg or placebo in a 1:1:1:1 ratio for up to 48 weeks. The primary endpoint was change in HVPG (ΔHVPG) at week 24. Secondary endpoints were changes in biomarkers (aminotransferases, caspases, cytokeratins) and development of liver-related outcomes. RESULTS: There were no significant differences in ΔHVPG for any emricasan dose vs. placebo (-0.21, -0.45, -0.58 mmHg, respectively) adjusted for baseline HVPG, compensation status, and non-selective beta-blocker use. Compensated patients (n = 201 [76%]) tended to have a greater decrease in HVPG (emricasan all vs. placebo, p = 0.06), the decrease being greater in those with higher baseline HVPG (p = 0.018), with a significant interaction between baseline HVPG (continuous, p = 0.024; dichotomous at 16 mmHg [median], p = 0.013) and treatment. Biomarkers decreased significantly with emricasan at week 24 but returned to baseline levels by week 48. New or worsening decompensating events (∼10% over median exposure of 337 days), progression in model for end-stage liver disease and Child-Pugh scores, and treatment-emergent adverse events were similar among treatment groups. CONCLUSIONS: Despite a reduction in biomarkers indicating target engagement, emricasan was not associated with improvement in HVPG or clinical outcomes in patients with NASH-related cirrhosis and severe portal hypertension. Compensated patients with higher baseline HVPG had evidence of a small treatment effect. Emricasan treatment appeared safe and well-tolerated. LAY SUMMARY: Cirrhosis (scarring of the liver) is the main consequence of non-alcoholic steatohepatitis (NASH). Cirrhosis leads to high pressure in the portal vein which accounts for most of the complications of cirrhosis. Reducing portal pressure is beneficial in patients with cirrhosis. We studied the possibility that emricasan, a drug that improves inflammation and scarring in the liver, would reduce portal pressure in patients with NASH-related cirrhosis and severe portal hypertension. Our results in a large, prospective, double-blind study could not demonstrate a beneficial effect of emricasan in these patients. CLINICAL TRIAL NUMBER: Clinical Trials.gov #NCT02960204.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2019. PMID: 31870950. doi:10.1016/j.jhep.2019.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。